-
Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeks' gestation.
Papastefanou I, Wright D, Syngelaki A, Souretis K, Chrysanthopoulou E, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:52-61. pdf -
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:408-415. pdf -
Ophthalmic artery Doppler in combination with other biomarkers in the prediction of pre-eclampsia at 35-37 weeks' gestation.
Sarno M, Wright A, Vieira N, Sapantzoglou I, Charakida M, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:600-606. pdf -
Competing-risks model for prediction of small-for-gestational-age neonates from maternal characteristics, serum PAPP-A and PlGF at 11-13 weeks' gestation.
Papastefanou I, Wright D, Lolos M, Anampousi K, Mamalis M, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:392-400 pdf -
Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A, Wright A, Panaitescu A, Syngelaki A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2019;220:584.e1-584.e11. pdf -
Impaired placental perfusion and major fetal cardiac defects.
Fantasia I, Andrade W, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;53:68-72. pdf -
Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A, Jabak S, De Castro H, Frei L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:79-86. pdf -
Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A, Ciobanu A, Syngelaki A, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:501-506. pdf -
Fetal major cardiac defects and placental dysfunction at 11-13 weeks' gestation.
Fantasia I, Kasapoglu D, Kasapoglu T, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;51:194-198. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-212. pdf -
Analysis of Cell-Free DNA in Maternal Blood in Screening For Aneuploidies: Updated Meta-Analysis.
Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:302-314. pdf -
Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in the prediction of preeclampsia.
Andrietti S, Carlucci S, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Comparison of screening for preeclampsia at 31-34 weeks' gestation by the sFLT to PLGF ratio and a method combining maternal factors with sFLT-1 and PLGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-208. -
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf